Drug Licensing Advisory for Brazil & Latin America
We connect global innovators with established Latin American licensees — and give both sides the intelligence to move with confidence. From asset scouting to signed deal to a healthy alliance, one partner across the region.
For originators — US & EU biotech
Reach Latin American patients and revenue without building an affiliate. We identify the right regional licensees for your asset, size the market with real regulatory and access context, and support the deal from first contact through signing — then keep the alliance healthy afterward.
For Latin American licensees
A systematic pipeline of licensable assets matched to your therapeutic focus. We scout US and European innovators, deliver licensing-ready dossiers with market sizing and competitive context, open the door, and support diligence and negotiation through to signature.
What the practice covers
Five services, engaged together or à la carte.
Asset Scouting & Sourcing
Systematic identification of licensable assets across US and European biotech — screened for regulatory status, rights availability, and fit with a licensee’s focus and infrastructure.
Licensing-Ready Dossiers & Market Intelligence
Concise asset dossiers, market sizing, competitive landscape, and regulatory-pathway context — powered by BioAlma, our AI intelligence platform.
Deal Structuring & Negotiation Support
From first contact to signed agreement: outreach, diligence coordination, term framing, and negotiation support on either side of the table.
Alliance Management
Licensing deals live for years. Ongoing governance, reporting, and neutral bilingual coordination between originator and licensee — keeping the partnership healthy long after signature.
Brazil & LatAm Market Entry
Regulatory pathway (ANVISA and beyond), pricing and access landscape, and entry strategy for companies bringing an approved asset to Latin America.
How we work
Map
Landscape and shortlist. We map the asset or partner universe and score it against your criteria — therapeutic fit, regulatory status, rights, and commercial logic.
Engage
Doors opened. Structured outreach, first meetings, diligence questions, and term framing — with a physician-executive in the room, not a broker.
Sustain
Deals that last. Alliance management and in-market intelligence after signing, so the partnership performs for both sides.
Why SambaTrials
Physician-executive partners
MD/PhD operators who have run medical affairs, corporate development, and clinical operations inside biotech — over half a billion dollars of transaction experience across business and corporate development.
Intelligence to execution
Every mandate runs on BioAlma, our AI intelligence platform — and connects to our clinical development practice on the ground in Brazil. São Paulo · San Diego.
Licensing in Latin America — FAQ
When should a biotech consider licensing in Latin America?
Typically at Phase 3, filing, or approval — when the asset’s value is established but building a direct affiliate isn’t justified. Licensing converts a region you weren’t going to serve into non-dilutive revenue. Earlier conversations make sense when a regional partner can also bring development or trial value.
How do licensing deals in Latin America typically work?
Most follow one of two structures: a full license (upfront, milestones, and royalties, with the licensee handling registration and commercialization) or a distribution/supply arrangement (the originator sells finished product at a transfer price). The right structure depends on the asset, the regulatory path, and both sides’ infrastructure.
Do you work with rare-disease assets?
Yes — rare disease is a core focus. Brazil’s public system reimburses several ultra-orphan therapies, regional specialty companies actively in-license rare-disease assets, and genetic-diagnosis programs and patient associations make these markets more identifiable than many expect.
How long until a licensed asset reaches its first sale in Brazil?
Plan on a multi-year path from signature to first commercial sale — ANVISA registration, pricing, and access decisions each take time, and in our experience a foreign company typically needs around three years to complete all registrations. An established local licensee usually moves materially faster; we factor this into deal terms.
Do you represent buyers or sellers?
Both, non-exclusively — buy-side mandates for regional licensees building a pipeline, and sell-side work for originators seeking partners. Engagement structure is disclosed up front; we don’t take undisclosed fees from both sides of the same deal.
Have an asset — or looking for one?
Talk to the partners. We’ll tell you quickly whether Latin America is worth it for your asset, and what the path looks like.
Start the Conversation